- Tytuł:
- Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
- Autorzy:
- Źródło:
- In Leukemia Research June 2023 129
Czasopismo naukowe